Stella Pharma Corporation (TYO:4888)

Market Cap	11.63B +3.6%
Revenue (ttm)	323.00M -66.4%
Net Income	-780.00M
EPS	-22.93
Shares Out	35.03M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	307,700
Open	332.00
Previous Close	332.00
Day's Range	330.00 - 349.00
52-Week Range	200.00 - 995.00
Beta	0.27
Analysts	n/a
Price Target	n/a
Earnings Date	May 13, 2026

About Stella Pharma

Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its products include SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma, meningioma, and malignant melanoma and angiosarcoma. The company was incorporated in 2007 and is headquartered in Osaka, Japan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 43
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4888

Financial Performance

In fiscal year 2026, Stella Pharma's revenue was 323.00 million, a decrease of -66.39% compared to the previous year's 961.00 million. Losses were -780.00 million, 457.1% more than in 2025.